Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms.
From March 17th, 2020 to May 11th 2002, the French government has implemented national containment measures due to the Covid-19 epidemic.
Although there are data on the psychological impact and experience of quarantine measures in people who have been infected or suspected of being carriers of certain pathogens (e.g. Ebola), there are no data on such impact in the French population and quarantines lasting longer than 21 days. Investigators therefore propose to conduct a human and social sciences study in order to better understand the current situation
The main objective is to describe the psychological state during confinement (and the impact of the confinement) in a sample of the French general population.
Secondary objectives :
It is expected to highlight :
Self-questionnaires (Google form format) are sent by mailing lists or social networks to participants in order to complete the assessment of psychological state. A unique identifier is sent in a separate email. These assessments are performed at least once during the confinement period. It is planned to repeat them when the confinement is lifted: 15 days, 3 and 6 months after the lifting of the confinement because of the risk of developing anxiodepressive symptoms, in particular post-traumatic stressors.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Confined patients | General population |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Slef questionnaires fulfilment | Other | Questionnaires to assess the psychological impact of confinement and its evolution over 6 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Depressive Symptomatology | depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27) | during confinement |
| Measure | Description | Time Frame |
|---|---|---|
| Depressive Symptomatology | depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27) | post-confinement : 15 days, 3 months, 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Psychological pain | Psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10) | during confinement |
| sleep | quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28) |
Inclusion criteria:
- age> 18
Exclusion criteria:
- protective measure (curatorship, guardianship)
Not provided
Not provided
Not provided
Adults who agree to participate by answering the questionnaires
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emilie Olie, MD PhD | Contact | +33 4 67 33 85 81 | e-olie@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Emilie Olie, MD PhD | University Hospital, Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University hospital | Recruiting | Montpellier | 34295 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
Not provided
Not provided
Not provided
Not provided
Not provided
| during confinement |
| sleep | quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28) | post-confinement (15 days, 3 months, 6 months) |
| anxiety | anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21) | during confinement |
| anxiety | anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21) | post-confinement (15 days, 3 months, 6 months) |
| psychological pain | psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10) | post-confinement (15 days, 3 months, 6 months) |
| physical pain | psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10) | during confinement |
| physical pain | psychological pain : likert scale higher score, more psychological pain-> min : 0 max : 10) | post-confinement (15 days, 3 months, 6 months) |
| anger | staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50) | during confinement |
| anger | staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50) | post-confinement (15 days, 3 months, 6 months) |
| Stressful Event Impact | Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45) ) | during confinement |
| Stressful Event Impact | Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45) | post-confinement (15 days, 3 months, 6 months) |
| Use of psychotropic drugs | Number of patients declaring an increase of psychotropic drug use | during confinement |
| Use of psychotropic drugs | Number of patients declaring an increase of psychotropic drug use | post-confinement (15 days, 3 months, 6 months) |
| Tobacco consumption | Number of patients declaring an increase of tobacco consumption | during confinement |
| Tobacco consumption | Number of patients declaring an increase of tobacco consumption | post-confinement (15 days, 3 months, 6 months) |
| alcohol consumption | Number of patients declaring an increase of alcohol consumption | post-confinement (15 days, 3 months, 6 months) |
| alcohol consumption | Number of patients declaring an increase of alcohol consumption | confinement |
| Illicit substances consumption | Number of patients declaring an increase of illicit substances consumption | confinement |
| Illicit substances consumption | Number of patients declaring an increase of illicit substances consumption | post-confinement (15 days, 3 months, 6 months) |
| orientation of life | Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24 | confinement |
| orientation of life | Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24 | post-confinement (15 days, 3 months, 6 months) |
| D012141 |
| Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |